Organigram (NASDAQ:OGI - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, February 11th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $48.94 million for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.
Organigram (NASDAQ:OGI - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.02). Organigram had a negative return on equity of 11.68% and a negative net margin of 28.58%. On average, analysts expect Organigram to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Organigram Trading Down 6.2 %
OGI traded down $0.09 during trading on Wednesday, hitting $1.35. 3,012,690 shares of the company's stock traded hands, compared to its average volume of 835,627. The stock has a market capitalization of $170.32 million, a price-to-earnings ratio of -3.55 and a beta of 1.00. The company's 50 day simple moving average is $1.57 and its two-hundred day simple moving average is $1.67. Organigram has a 12-month low of $1.29 and a 12-month high of $2.91.
Organigram Company Profile
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Further Reading
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
